Swept-source optical coherence tomography (OCT) may be superior to enhanced depth imaging (EDI)-OCT in imaging the posterior sclera, but not in imaging the lamina cribrosa, according to a study published online in the American Journal of Ophthalmology.
Swept-source optical coherence tomography (OCT) may be superior to enhanced depth imaging (EDI)-OCT in imaging the posterior sclera, but not in imaging the lamina cribrosa, according to a study published on-line in the American Journal of Ophthalmology.
Researchers from The Catholic University of Korea, Seoul, obtained both EDI-OCT and swept-source OCT images in 32 myopic patients with glaucoma. B-scan images were used to obtain subfoveal choroidal, subfoveal scleral, and central laminar thicknesses, performed at three locations by two masked observers.
With EDI-OCT, the posterior border of the sclera was visible in 31% of eyes, compared with 53% using swept-source OCT. Using McNemar's Χ2-test, detection of the posterior border of the sclera was significantly different between the two imaging modalities (P = 0.008), while that of the posterior border of the lamina cribrosa was similar. In highly myopic eyes, the detection rate of the posterior border of the sclera and lamina cribrosa was not significantly different. Intersystem intraclass correlation coefficient (ICC) was 0.769 for subfoveal scleral thickness and 0.900 for laminar thickness. Mean subfoveal scleral thickness was 464.32 μm with EDI-OCT, compared with 650.26 μm with swept-source OCT, a statistically significant difference (P = 0.018).
To view a copy of the abstract, click here.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.